Clinical trial
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and…
NCT00436566 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00436566 |
|---|---|
| Title | Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery |
| Official title | Phase II Study of Cardiac Safety and Tolerability of an Adjuvant Chemotherapy Plus Trastuzumab With Lapatinib in Patients With Resected HER2 + Breast Cancer |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Cardiac Toxicity |
| Intervention type | Biological, Drug, Genetic, Other, Procedure |
| Interventions | trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, gene expression analysis, reverse transcriptase-polymerase chain reaction, fluorophotometry, laboratory biomarker analysis, mass spectrometry and 2 more |
| Enrollment | 122 |
| Start date | Mar 16, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Jul 22, 2019 |
| First posted | Feb 19, 2007 |
| Last update posted | Aug 5, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: